| I-05 Bram Agema Development of covariate-informed model pooling method to predict the correct starting dose Wednesday 10:00-11:30 |
| I-06 Ana Alarcia Lacalle Population pharmacokinetic modelling and Monte Carlo simulation of piperacillin administered as extended infusion in critically ill patients Wednesday 10:00-11:30 |
| I-15 Carla Bastida Fernández Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections Wednesday 10:00-11:30 |
| I-18 Laura Ben Olivo Model-informed precision dosing web tool of busulfan for Brazilian pediatric patients Wednesday 10:00-11:30 |
| I-33 Anthea Deschamps Pharmacokinetics of cefotaxime in intensive care patients: exploration of the sources of variability with a population model Wednesday 10:00-11:30 |
| I-36 Kevin Dykstra Population pharmacokinetics of vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for treatment of anemia associated with chronic kidney disease Wednesday 10:00-11:30 |
| I-37 Omar Elkayal Model-based dose optimisation of intravenous posaconazole for treatment of patients with invasive aspergillosis in the intensive care unit Wednesday 10:00-11:30 |
| I-57 Nick Holford A Physiological Approach to Renal Clearance - from Premature Neonates to Adults Wednesday 10:00-11:30 |
| I-70 Sjoerd Koopman Bayesian forecasting of recombinant factor IX-Fc fusion protein concentrate dosing in haemophilia B patients: Comparison of the performance of two population pharmacokinetic models Wednesday 10:00-11:30 |
| III-31 Donghwan Lee A comparative population pharmacokinetic analysis of nafamostat mesilate in patients receiving extracorporeal membrane oxygenation therapy (ECMO) support: central venous samples vs. ECMO circuit samples Thursday 10:15-11:45 |
| III-38 Han Liu Informing the selection of clinically relevant pharmacokinetic target range for Therapeutic Drug Monitoring (TDM) of sunitinib: a pharmacometric simulation framework Thursday 10:15-11:45 |
| III-49 Emir Mesic Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia Thursday 10:15-11:45 |
| III-56 Frances Okibedi Investigating Alternative Daily Dose Regimens for Bedaquiline in Treatment of Multidrug-Resistant Tuberculosis using an Interactive Shiny Application Thursday 10:15-11:45 |
| III-74 Darlene Santiago A Pharmacometric approach for opioid use disorder in Puerto Rico: A research agenda to individualize buprenorphine pharmacotherapy. Thursday 10:15-11:45 |
| III-78 Raman Sharma A meta-analysis for predicting early bactericidal activity of beta-lactam antibiotics against pulmonary tuberculosis Thursday 10:15-11:45 |
| III-85 Huybrecht T'jollyn Individual virtual controls as surrogate for a control arm – application for siRNA and NA therapy in chronic hepatitis B infection Thursday 10:15-11:45 |
| III-88 Paul Thoueille Pharmacometrics-based analysis of long-acting cabotegravir over 6 months in real-life people living with HIV in Switzerland Thursday 10:15-11:45 |
